

TTY BIOPHARM COMPANY LIMITED
2026 Annual Shareholders' Meeting Minutes
【Translation】

Time: May 28, 2026 (Thursday) 9:00 AM

Location: 2F, No.19-10, Sanchong Rd., Nangang District, Taipei City

(International Convention Center, 2F, Building A, Nangang Software Park)

Meeting type: Physical Shareholders' Meeting

Total outstanding TTY shares: 248,649,959 shares

Total shares represented by shareholder present in person or by proxy: 200,120,160 shares

Percentage of shares held by shareholder present in person or by proxy: 80.43%

Director Present: Chuan Lin, Wen-Hwa Chang, Carl Hsiao, Ying-Ying Liao, Ming-Ling Hsueh (Independent Director), Ann-Lii Cheng (Independent Director), Ming-Dao Chang (Independent Director & Chairman of the Audit Committee)

Attendance: Ching-Lan Hou, General Manager ; Yi-Lien Han, CPA of KPMG ; Wen-Peng Lin , Lawyer of Giant Era International Law Office

Chairman: Chuan Lin

Recorder: Kuo-Chiang Chang

Meeting procedures

I. Calling to the Meeting Order

The aggregate shareholding of the shareholders present in person or by proxy constituted a quorum. The Chairman called the meeting to order.

II. Chairman's Address (omitted)

III. Report Items

1. Business Report for Fiscal Year 2025. (Please refer to Attachment 1)
2. Audit Committee's Review Report on the 2025 Financial Reports. (Please refer to Attachment 2)
3. Report on Communication between Audit Committee Members and the Head of Internal Audit. (Please refer to Attachment 3)
4. Report on the Distribution of Employee and Director Compensation for Fiscal Year 2025. (Please refer to Handbook)
5. Report on Directors' Remuneration Paid for Fiscal Year 2025. (Please refer to Attachment 4)
6. Report on the Distribution of Cash Dividends from 2025 Earnings. (Please refer to Handbook)
7. Report on Material Related Party Transactions for 2025. (Please refer to Handbook)

IV. Ratification Items

Item One:

(Proposed by the Board of Directors.)

Proposal: The Company's Business Report and Financial Reports for 2025.

Explanation:

1. The Company's Business Report, Financial Reports, and Consolidated Financial Reports for 2025 have been reviewed and approved by the Audit Committee and resolved by the Board of Directors.
2. The Financial Reports and Consolidated Financial Reports have been audited by CPAs Yi-Lien Han and Shu-Ying Chang of KPMG, who have issued an unqualified audit report.
3. The Company's Business Report, Financial Reports, and Consolidated Financial Reports for 2025 are presented in Attachment 1 and Attachment 5.

Voting Results :

Shares represented at the time of voting:200,120,160

| Voting Results | Percentage of the total represented share present |
|--|---|
| Votes in favor:188,280,463 votes (including 51,816,970 electronic votes) | 94.08% |
| Votes against: 9,773 votes (including 9,773 electronic votes) | 0.00% |
| Votes invalid:0 votes | 0.00% |
| Votes abstained and not voted: 11,829,924 votes (including 11,709,924 electronic votes) | 5.91% |

Resolution : RESOLVED, 94.08% of total represented voting rights present voted for and this proposal was approved as proposed.

Item Two:

(Proposed by the Board of Directors.)

Proposal: The Proposal for Distribution of 2025 Earnings.

Explanation:

The Board of Directors has approved the Company's Earnings Distribution Table for 2025, which has been reviewed by the Audit Committee. Please refer to Attachment 6.

Voting Results :

Shares represented at the time of voting:200,120,160

| Voting Results | Percentage of the total represented share present |
|--|---|
| Votes in favor: 188,505,487 votes (including 52,041,994 electronic votes) | 94.19% |
| Votes against: 10,756 votes (including 10,756 electronic votes) | 0.00% |
| Votes invalid:0 votes | 0.00% |
| Votes abstained and not voted: 11,603,917 votes (including 11,483,917 electronic votes) | 5.97% |

Resolution : RESOLVED, 94.19% of total represented voting rights present voted for and this proposal was approved as proposed.

V. Discussion Items

Item One: (Proposed by the Board of Directors.)

Proposal: Amendment to the Company’s “Procedures for Acquisition or Disposal of Assets”.

Explanation:

1. In response to operational requirements, certain provisions of the Company’s “Procedures for Acquisition or Disposal of Assets” have been amended.
2. For a comparison of the provisions before and after amendment to the “Procedures for Acquisition or Disposal of Assets,” please refer to Attachment 7.

Voting Results :

Shares represented at the time of voting:200,120,160

| Voting Results | Percentage of the total represented share present |
|--|---|
| Votes in favor:171,188,768 votes (including 34,725,275 electronic votes) | 85.54% |
| Votes against: 17,319,366 votes (including 17,319,366 electronic votes) | 8.65% |
| Votes invalid:0 votes | 0.00% |
| Votes abstained and not voted: 11,612,026 votes (including 11,492,026 electronic votes) | 5.80% |

Resolution : RESOLVED,85.54% of total represented voting rights present voted for and this proposal was approved as proposed.

Item Two: (Proposed by the Board of Directors.)

Proposal: Exemption from Non-Competition Restrictions for Directors.

Explanation:

1. Pursuant to Article 209 of the Company Act, the additional competitive activities engaged in by the Company's directors and their representatives are hereby disclosed, and shareholders are requested to grant approval exempting such directors and their representatives from non-competition restrictions.
2. The details of newly assumed concurrent positions held by the Company's directors and their representatives are as follows:

| Title | Name | Details of Newly Assumed Concurrent Positions |
|----------|--|--|
| Director | Dawan Technology Co., Ltd. Representative: Carl Hsiao | Director of American Taiwan Biopharma Philippines Inc. Director of Medpace Taiwan Co., Ltd. |

Voting Results :

Shares represented at the time of voting:200,120,160

| Voting Results | Percentage of the total represented share present |
|--|---|
| Votes in favor: 184,914,746 votes (including 48,451,253 electronic votes) | 92.40% |
| Votes against: 168,359 votes (including 168,359 electronic votes) | 0.08% |
| Votes invalid:0 votes | 0.00% |
| Votes abstained and not voted: 15,037,055 votes (including 14,917,055 electronic votes) | 7.51% |

Resolution : RESOLVED, 92.40% of total represented voting rights present voted for and this proposal was approved as proposed.

VI. Extraordinary Motions: None.

VII. Adjournment: The Chairman announced the meeting adjourned at 9:21 am on May 28, 2026.

(There is no question from shareholders at this Annual General Shareholders' Meeting; the minutes of the shareholders' meeting record the essentials and results, the contents, procedures and shareholder speeches of the meeting are still subject to the audio-visual records of the meeting.)

Attachment 1

TTY Biopharm Company Limited BUSINESS REPORT

I. Operating Results for 2025

(I) Implementation Results of Business Plan

The company's consolidated net operating revenue for 2025 was NT\$6,452,948 thousand, an increase of NT\$5,893,847 thousand or 9.49% compared to NT\$559,101 thousand in 2024. This growth was primarily attributable to a significant increase in overseas business performance during 2025. Net profit attributable to the parent company for 2025 amounted to NT\$1,559,125 thousand, an increase of NT\$109,503 thousand, or 7.55%, compared to NT\$1,449,622 thousand for 2024. The increase was primarily attributable to higher operating revenues in 2025, which drove overall improvement in operating income and net profit for the period.

(II) Budget Implementation

The company's 2025 individual net operating revenue was NT\$5,407,764 thousand, with pre-tax net profit of NT\$1,559,125 thousand, achieving 124.01% of the annual budget target.

(III) Financial Receipts, Expenditures, and Profitability Analysis

| Item | | Year | |
|-------------------------------------|----------------------------------|--------|--------|
| | | 2025 | 2024 |
| Financial Receipts and Expenditures | Interest Income (thousand NT\$) | 13,221 | 10,121 |
| | Interest Expense (thousand NT\$) | 38,010 | 38,337 |
| Profitability Analysis | Return on Assets (%) | 15.70 | 15.48 |
| | Return on Equity (%) | 22.29 | 22.84 |
| | Net Profit Margin (%) | 28.83 | 29.08 |
| | Earnings Per Share (NT\$) | 6.27 | 5.83 |

(IV) R&D Status

TTY Biopharm possesses professional pharmaceutical development and manufacturing capabilities, offering comprehensive solutions that encompass drug delivery systems and complete Contract Development and Manufacturing Organization (CDMO) services. From formulation development, analytical method development, process development, animal testing, and functional excipient synthesis to human clinical trials, GMP production, and CMC documentation preparation, all processes comply with international standards. This ensures research and development outcomes can be effectively translated into clinical applications, while remaining committed to a patient-centric approach and enhancing healthcare accessibility.

The Company continues to advance research and development innovation and enhance its competitiveness in global markets, with a focus on developing high-barrier specialty dosage form drugs, biologics, and innovative pharmaceuticals, thereby ensuring diversity within its product portfolio and sustaining competitive advantages. Through comprehensive disease product lines covering anti-cancer drugs, critical care medicines, and vaccines, TTY Biopharm provides diverse solutions while actively investing in therapeutic areas with high market growth potential, ensuring research achievements can be rapidly converted into commercial value.

Looking ahead, TTY Biopharm will continue to innovate and focus on developing specialized drug delivery technology platforms. By strengthening technological advantages, international collaboration, and market expansion, the company will continuously enhance its competitive edge.

II. Summary of Business Plan for 2026

(I) Management Policy

TTY Biopharm upholds the vision of “Enhancing Human Life Quality Through Scientific Technology” and continues to pursue excellence and stable growth, successfully positioning itself as “an innovative international biotech pharmaceutical company focused on specialized dosage form development and new drug research.” The company’s strategy will focus on research, development, and manufacturing of high value-added pharmaceuticals, expanding into international markets, and strengthening competitive advantages in high-barrier specialized dosage forms and biologics to secure its global market position. To accelerate internationalization, TTY Biopharm is actively deploying resources in the United States, Europe, and emerging markets through direct operations and strategic alliances, while optimizing pharmaceutical product lines through proprietary research and technology licensing to meet diverse market demands. In the future, the company will pursue its mission of “Providing Diverse Medical Solutions for Patients Worldwide,” focusing on cancer treatment and critical anti-infection fields and becoming an international-level biotech pharmaceutical company that creates greater value for the global healthcare industry.

(II) Expected Sales Volume and Its Basis

For 2026, the company forecasts sales of 423,786 thousand oral dosage units and 6,116 thousand injectable units. The company’s expected sales volume is based on IQVIA statistical reports, while also considering potential future market supply and demand changes, new product development speed, and national health insurance policies.

(III) Important Production and Sales Policies

TTY Biopharm adheres to three core strategies — “Export of Difficult-to-Manufacture Generic Drugs,” “In-Licensing of International New Drugs,” and “Self-Manufactured Domestic New Drugs,” and continues to forge new growth trajectories upon its established foundation. The company continues to optimize its production and sales policies to meet market demands and enhance competitive advantages, expanding market share and strengthening brand influence.

TTY Biopharm continues to deepen its international market deployment. While steadily operating in the Taiwan market, the company is actively expanding into Asian, European, American, and other emerging markets through direct operations and strategic partnerships to enhance brand competitiveness and revenue momentum. The company will strengthen product competitiveness in core areas such as oncology, critical care, vaccines, and anesthetic drugs, while actively introducing innovative international pharmaceuticals to meet the needs of various regional markets. Simultaneously, manufacturing facilities will be optimized according to market and regulatory requirements to ensure compliance with

international quality standards while improving production efficiency. Additionally, by strengthening supply chain management to reduce costs and ensure market competitive advantage, TTY Biopharm will continue to solidify its competitiveness in the global market.

III. Future Company Development Strategy

Corporate Vision: “Enhancing Human Life Quality Through Scientific Technology.”

Corporate Mission and Strategies: “Dedicated to developing and manufacturing specialized dosage form drugs (patentable or with high-barrier characteristics), biologics, new medical technologies, and new drugs to perfect TTY’s product portfolio; continuously strengthening the R&D platform for high-barrier dosage form drugs and extending their benefits to various disease domains”; “Specializing in and deepening international development in the areas of anti-cancer, critical care, anti-infection, and specialized dosage form drug development and manufacturing”; “Becoming one of the world’s most innovative biotech pharmaceutical companies”; “Being the best partner for international biotech pharmaceutical companies in drug development and international market marketing.”

In its future development, TTY Biopharm will endeavor to bring successive R&D outcomes through regulatory approval and to market, maximizing their commercial impact, while continuing to expand international market channels and actively pursuing opportunities for international collaboration. The Company’s development objectives will be achieved through the following key strategies:

1. Optimizing the product portfolio and target selection to encompass diverse therapeutic areas and to balance early-, mid-, and late-stage drug development, thereby ensuring sustained enhancement of corporate competitiveness, revenue growth, and value chain integration.
2. Deepening international cooperation, promoting innovative R&D, and accelerating the development of high technical threshold drugs that meet unmet medical needs, including specialized dosage form generics, new drugs, and drug delivery platforms. This will strengthen technical and manufacturing advantages, enhance international market competitiveness and brand visibility, and expand global business territory.
3. Keeping abreast of international regulatory dynamics and optimizing and upgrading manufacturing facilities to maintain competitive advantages. Simultaneously strengthening the CDMO (Contract Development and Manufacturing Organization) business model to enhance service capabilities in international markets and expand global business territory.
4. Enhancing manufacturing capacity and supply chain management through acquisitions, strategic alliances, and joint ventures; strengthening the integration of R&D and production; optimizing end-to-end management from drug development to manufacturing; and ensuring production efficiency and market competitiveness.
5. Continuously optimizing production processes to ensure the supply chain has international mass production capabilities. Simultaneously expanding production capacity scale through precise resource investment and profit/loss assessment to improve cost-effectiveness, ensure market competitive advantages, and strengthen international market supply capabilities and competitiveness.
6. Introducing international talent to enhance global competitiveness, and integrating cross-disciplinary expertise through organizational revitalization and management innovation. Anchoring organizational development in the four pillars of “science, regulations, business operations, and supply chain management” and building a leadership team with a global perspective to drive the Company toward a new phase of internationalization.
7. Continuously optimizing internal organizational structure based on operational strategy and synergy considerations to improve operational efficiency and overall competitiveness.

Simultaneously promoting standardization of licensing agreements to accelerate international business partnerships, expand domestic and overseas markets, strengthen global business deployment, and ensure maximization of company interests.

IV. Impact of External Competitive Environment, Regulatory Environment, and Macroeconomic Environment

In the face of increasingly intense competition in global markets and continued supply chain uncertainty in the post-pandemic era, TTY Biopharm continues to strengthen its capacity to respond to external environmental changes and to optimize production and operations management, ensuring stable supply and meeting market demand. Concurrently, in response to evolving regulatory landscapes in the United States and European markets, the Company will conduct rolling reviews and adjustments of its compliance strategies to ensure adherence to the regulatory standards of each jurisdiction and to sustain its competitive advantages in international markets.

To reduce operational risks and enhance corporate resilience, the company will deepen capital operations and cost control, optimize market response mechanisms, and diversify market risks through strategic cooperation and licensing agreements. These efforts will expand business deployment, improve profitability, ensure long-term stable development, and continuously strengthen global market competitiveness.

Chairman: Chuan Lin

President: Ching-Lan Hou

Chief Accountant: Wei-Chuan Wang

Attachment 2

TTY Biopharm Company Limited

Audit Committee's Review Report

The Board of Directors has submitted the Company's 2025 Business Report, Financial Statements (including Consolidated Financial Statements), and Profit Distribution Proposal. The Financial Statements (including Consolidated Financial Statements) have been audited by CPAs Yi-Lien Han and Shu-Ying Chang of KPMG, who have issued audit reports. The aforementioned documents have been examined by the Audit Committee and found to be accurate and complete. This report is hereby submitted in accordance with Article 14-4 of the Securities and Exchange Act and Article 219 of the Company Act for your review and approval.

Respectfully submitted to

The 2026 Annual Shareholders' Meeting of TTY Biopharm Company Limited

Convener of the Audit Committee, Ming-Dao Chang

March 9, 2026

Attachment 3

TTY Biopharm Company Limited

Communication between the Audit Committee Members and the Head of Internal Audit in 2025

According to the Company’s “Regulations on Communication Procedures between the Audit Committee and the Internal Audit Unit,” the Head of Internal Audit shall report to the Independent Directors on audit operations, communicate audit findings, report on the implementation and effectiveness of follow-up actions, and discuss the annual audit plan at least quarterly during Audit Committee meetings. Additionally, a private meeting between the Independent Directors and the Head of Internal Audit is held annually to thoroughly communicate on issues of concern to the Independent Directors. The Independent Directors also evaluate the overall performance of the internal audit annually and provide recommendations for audit focus areas for the following year.

The summary of communications between the Audit Committee members and the Head of Internal Audit for fiscal year 2025 is as follows:

| Date | Key Communication Points | Implementation Results |
|--|---|--|
| 2025/02/25 5th meeting of the 4th term Audit Committee Meeting | Report on Internal Control Audit Items from December 2024 to January 2025 | No comments from Independent Directors |
| 2025/05/14 6th meeting of the 4th term Audit Committee Meeting | Report on Internal Control Audit Items from February to March 2025 | No comments from Independent Directors |
| 2025/08/05 7th meeting of the 4th term Audit Committee Meeting | Report on Internal Control Audit Items from April to June 2025 | No comments from Independent Directors |
| 2025/11/06 8th meeting of the 4th term Audit Committee Meeting | Report on audit items from July to September 2025 | No comments from Independent Directors |
| 2025/12/22 Private meeting between the Head of Internal Audit and Independent Directors | <ol style="list-style-type: none"> 1. Audit Plan for fiscal year 2026 2. Implementation of corresponding measures for ERP system integration 3. Continued use of technology to improve audit efficiency 4. 2026 Performance Evaluation Criteria | No comments from Independent Directors |

Attachment 4

Details of Directors' Remuneration for 2025

Remuneration of Non-Independent Directors and Independent Directors:

Unit: NTD Thousands

| Title | Name | Directors' Remuneration | | | | | | | | Total of items A, B, C, and D and ratio to Net Income After Tax (%) | | Remuneration received as an employee | | | | | | | | Total of items A, B, C, D, E, F, and G and ratio to Net Income After Tax (%) | | Remuneration received from investees other than subsidiaries or from the parent company | | | |
|---|----------------------|----------------------------|--|--------------------------------|--|-----------------------------|--|--------------------------------------|--|---|--|--|--|--------------------------------|--|---------------------------|--------------|-------------|--------------|--|--|---|-----------|-----------|------|
| | | Compensation (A) | | Severance Pay and Pensions (B) | | Directors' Remuneration (C) | | Allowances for Business Execution(D) | | | | Salary, Bonuses, and Special Disbursements (E) | | Severance Pay and Pensions (F) | | Employee Remuneration (G) | | | | | | | | | |
| | | The Company | All Companies in the Financial Reports | The Company | All Companies in the Financial Reports | The Company | All Companies in the Financial Reports | The Company | All Companies in the Financial Reports | The Company | All Companies in the Financial Reports | The Company | All Companies in the Financial Reports | The Company | All Companies in the Financial Reports | Cash Amount | Stock Amount | Cash Amount | Stock Amount | The Company | All Companies in the Financial Reports | | | | |
| Non-Independent Directors | Chairman | Chuan Lin | 8,792 | 9,542 | 0 | 0 | 3,600 | 3,600 | 20 | 36 | 12,412.80 | 13,178.85 | 453 | 453 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12,866.83 | 13,632.87 | None |
| | Vice Chairman | Wen-Hua Chang | 240 | 240 | 0 | 0 | 2,400 | 2,400 | 20 | 20 | 2,660.17 | 2,660.17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,660.17 | 2,660.17 | None |
| | Director | Dawan Technology Co., Ltd. | 0 | 0 | 0 | 0 | 2,400 | 2,400 | 0 | 0 | 2,400.15 | 2,400.15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,400.15 | 2,400.15 | None |
| | | Representative: Carl Hsiao | 0 | 0 | 0 | 0 | 0 | 0 | 40 | 64 | 40.00 | 64.00 | 453 | 453 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 493.03 | 517.03 | None |
| | Director | Tze-Kaing Yang | 0 | 0 | 0 | 0 | 2,400 | 2,400 | 40 | 40 | 2,440.16 | 2,440.16 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,440.16 | 2,440.16 | None |
| | Director | Shih-Chang Hsu | 0 | 0 | 0 | 0 | 2,400 | 2,400 | 20 | 20 | 2,420.16 | 2,420.16 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,420.16 | 2,420.16 | None |
| Director | Ying-Ying Liao | 0 | 0 | 0 | 0 | 2,400 | 2,400 | 20 | 20 | 2,420.16 | 2,420.16 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,420.16 | 2,420.16 | None | |
| Independent Director | Independent Director | Ming-Ling Hsueh | 2,640 | 2,640 | 0 | 0 | 0 | 0 | 92 | 92 | 2,732.18 | 2,732.18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,732.18 | 2,732.18 | None |
| | Independent Director | An-Li Cheng | 2,640 | 2,640 | 0 | 0 | 0 | 0 | 92 | 92 | 2,732.18 | 2,732.18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,732.18 | 2,732.18 | None |
| | Independent Director | Ming-Dao Chang | 2,640 | 2,640 | 0 | 0 | 0 | 0 | 92 | 92 | 2,732.18 | 2,732.18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,732.18 | 2,732.18 | None |
| <p>1. Please describe the independent Directors' remuneration policy, system, standards, and structure, and explain the correlation between the remuneration amount and factors such as responsibilities, risks, and time commitment: The Company's independent Directors receive monthly compensation in accordance with the Company's "Directors' Remuneration Distribution Regulations" and do not participate in the annual distribution of directors' remuneration. Their compensation is determined with reference to industry standards and based on their level of participation in the Company's operations and the value of their contributions, as resolved by the Company's Remuneration Committee and Board of Directors.</p> <p>2. In addition to the disclosures in the above table, remuneration received by the Company's directors in the most recent fiscal year for providing services to all companies included in the financial reports (such as serving as non-employee consultants to the parent company/all companies in the financial reports/in businesses): None.</p> | | | | | | | | | | | | | | | | | | | | | | | | | |

Attachment 5

Independent Auditors' Report

To the Board of Directors
TTY Biopharm Company Limited:

Opinion

We have audited the accompanying financial statements of TTY Biopharm Company Limited (“the Company”), which comprise the balance sheets as of December 31, 2025 and 2024, the statements of comprehensive income, changes in equity and cash flows for the years then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, based on our audits and the report of another auditor (please refer to the Other Matter paragraph), the accompanying financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and its financial performance and its cash flows for the years then ended in accordance with the “Regulations Governing the Preparation of Financial Reports by Securities Issuers”.

Basis for Opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with The Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis of our opinion.

Other Matter

We did not audit the financial statements of PharmaEngine, Inc. Those statements were audited by another auditor, whose report has been furnished to us, and our opinion, insofar as it relates to the amounts included for certain equity-accounted investees, are based solely on the report of another auditor. The investment in PharmaEngine, Inc. accounted for using the equity method constituted 10.16% and 11.48% of total assets as of December 31, 2025 and 2024, respectively, and the related share of profit of associates accounted for using the equity method constituted 3.52% and 17.74% of pre-tax net income for the years ended December 31, 2025 and 2024, respectively.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. Key audit matters for the financial statements are stated as follows:

1. Occurrence of revenue from selling pharmaceuticals and chemical drugs

Please refer to Notes 4(p) of the financial statements for the accounting principles on revenue recognition. Revenues are recognized by net values of contract prices, less sales returns and allowances, after controls of the products are transferred to the customers.

Key audit matters:

The Company's sales is mainly from selling of pharmaceuticals and chemical drugs. Because the customers are diversity and numerous, it takes longer time to verify sales transactions. Therefore, the occurrence in sales transactions is one of the important issue in performing our audit procedures.

Auditing procedures performed:

- Testing the effectiveness of the design and implementing the internal control system of sales and collection operation;
- Testing the samples of sales transaction before and after the balance sheet date to ensure the correctness of sales revenue;
- Inspecting the related documents to ensure the adequacy and reasonableness of revenue recognition.

2. Inventory valuation

Please refer to Notes 4(g), and 5 of the financial statements for the accounting principles on the inventory valuation, significant accounting assumptions and judgments, and major sources of estimation uncertainty.

Key audit matters:

The Company's primary operating items are manufacturing and processing various kinds of pharmaceuticals. The pharmaceutical industry in Taiwan is susceptible to the constant amendments of its law, resulting in large price fluctuation of pharmaceutical products, which will affect the carrying value of inventories to exceed its net value. Because of these uncertainties, the Company's revenue and income may be effected by the price fluctuations. If the assessment of the net realizable value of the inventory is not appropriate, it will lead to a material misstatement of the financial statements. Therefore, the assessment of the allowance for inventory valuation loss is considered one of the key audit matters in our audit.

Auditing procedures performed:

- Overviewing the stock ageing list, and analyzing the movement of stock ageing by period;
- Obtaining the certificate documents to verify the correctness of the stock's expiry date; and
- Sampling the replacement cost and market price of inventories, and recalculating the net realizable value by marketing expense rate, to ensure the reasonableness of net realizable value adopted by the Company.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and for such internal control as management determines it is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance (including the Audit Committee) are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient and appropriate audit evidence regarding the financial information of the investment in other entities accounted for using the equity method to express an opinion on this financial statements. We are responsible for the direction, supervision and performance of the audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partners on the audit resulting in this independent auditors' report are Han, Yi-Lien and Chang, Stu-Ying.

KPMG

Taipei, Taiwan (Republic of China)
March 9, 2026

| | | December 31, 2025 | | December 31, 2024 | |
|----------------------------|---|----------------------|------------|-------------------|------------|
| | | Amount | % | Amount | % |
| Assets | | | | | |
| Current assets: | | | | | |
| 1100 | Cash and cash equivalents (notes 6(a)and (s)) | \$ 630,076 | 6 | 755,565 | 8 |
| 1150 | Notes receivable, net (notes 6(b)and (s)) | 9,275 | - | 11,824 | - |
| 1170 | Accounts receivable, net (notes 6(b)and (s)) | 1,166,102 | 11 | 1,067,466 | 11 |
| 1180 | Accounts receivable due from related parties, net (notes 6(b), (s)and 7) | 106,696 | 1 | 93,582 | 1 |
| 1200 | Other receivables, net (notes 6(s)and 7) | 34,875 | - | 22,120 | - |
| 130X | Inventories (note 6(c)) | 1,253,269 | 13 | 1,111,050 | 12 |
| 1410 | Prepayments | 44,080 | - | 40,627 | - |
| 1470 | Other current assets (note 6(i)) | 11,063 | - | 5,499 | - |
| | | <u>3,255,436</u> | <u>31</u> | <u>3,107,733</u> | <u>32</u> |
| Non-current assets: | | | | | |
| 1517 | Non-current financial assets at fair value through other comprehensive income (note 6(d) and (s)) | 11,992 | - | 11,992 | - |
| 1550 | Investments accounted for using equity method, net (note 6(e)) | 3,981,239 | 38 | 3,957,390 | 40 |
| 1600 | Property, plant and equipment (note 6(f)) | 2,166,088 | 21 | 2,214,990 | 22 |
| 1755 | Right-of-use assets | 2,080 | - | 566 | - |
| 1760 | Investment property, net(note 6(g)) | 110,440 | 1 | 111,192 | 1 |
| 1780 | Intangible assets (note 6(h)) | 164,224 | 2 | 118,558 | 1 |
| 1840 | Deferred tax assets(note 6(m)) | 62,949 | 1 | 54,289 | 1 |
| 1915 | Prepayments for business facilities | 10,071 | - | 36,203 | - |
| 1920 | Refundable deposits paid(note 6(s)) | 46,540 | - | 22,400 | - |
| 1984 | Other non-current financial assets(notes 6(i), (r), (s)and 8) | 457,072 | 5 | 176,817 | 2 |
| 1990 | Other non-current assets (note 6(i)) | 77,059 | 1 | 89,495 | 1 |
| | | <u>7,089,754</u> | <u>69</u> | <u>6,793,892</u> | <u>68</u> |
| | | <u>\$ 10,345,190</u> | <u>100</u> | <u>9,901,625</u> | <u>100</u> |

| | | December 31, 2025 | | December 31, 2024 | |
|---------------------------------|---|----------------------|------------|-------------------|------------|
| | | Amount | % | Amount | % |
| Liabilities and Equity | | | | | |
| Current liabilities: | | | | | |
| 2100 | Short-term borrowings (notes 6(j)and (s)) | \$ 700,000 | 7 | 1,200,000 | 12 |
| 2130 | Contract liabilities-current(note 6(p)) | 50,457 | 1 | 33,300 | 1 |
| 2150 | Notes payable (note 6(s)) | 1,844 | - | 33,867 | - |
| 2170 | Accounts payable (note 6(s)) | 246,124 | 2 | 262,323 | 3 |
| 2230 | Current tax liabilities | 296,609 | 3 | 196,308 | 2 |
| 2200 | Other payables (notes 6(q)and (s)) | 642,807 | 6 | 526,119 | 5 |
| 2280 | Current lease liabilities(note 6(s)) | 1,388 | - | 573 | - |
| 2300 | Other current liabilities | 11,568 | - | 14,515 | - |
| 2320 | Long-term liabilities, current portion (notes 6(k)and (s)) | 500,000 | 5 | 400,000 | 4 |
| | | <u>2,450,797</u> | <u>24</u> | <u>2,667,005</u> | <u>27</u> |
| Non-Current liabilities: | | | | | |
| 2540 | Long-term borrowings (notes 6(k)and (s)) | - | - | 100,000 | 1 |
| 2570 | Deferred tax liabilities (note 6(m)) | 363,185 | 3 | 359,239 | 4 |
| 2580 | Non-current lease liabilities (note 6(s)) | 701 | - | - | - |
| 2640 | Net defined benefit liability, non-current (note 6(l)) | 17,008 | - | 17,539 | - |
| 2645 | Guarantee deposits received(notes 6(s)and 7) | 3,180 | - | 3,190 | - |
| 2650 | Credit balance of investments accounted for using equity method (note 6(e)) | 5,060 | - | 4,204 | - |
| 2670 | Other non-current liabilities (note 6(s)) | 266,849 | 3 | - | - |
| | | <u>655,983</u> | <u>6</u> | <u>484,172</u> | <u>5</u> |
| | | <u>3,106,780</u> | <u>30</u> | <u>3,151,177</u> | <u>32</u> |
| Total liabilities | | | | | |
| Equity (note 6(n)): | | | | | |
| 3100 | Capital stock | 2,486,500 | 24 | 2,486,500 | 25 |
| 3200 | Capital surplus (note 6(e)) | 317,559 | 3 | 317,036 | 3 |
| 3310 | Legal reserve | 1,657,165 | 16 | 1,499,516 | 15 |
| 3320 | Special reserve | 198,071 | 2 | 198,071 | 2 |
| 3350 | Unappropriated retained earnings | 2,571,933 | 25 | 2,190,637 | 22 |
| 3400 | Other equity interest | 7,182 | - | 58,688 | 1 |
| | | <u>7,238,410</u> | <u>70</u> | <u>6,750,448</u> | <u>68</u> |
| | | <u>\$ 10,345,190</u> | <u>100</u> | <u>9,901,625</u> | <u>100</u> |

(English Translation of Financial Statements Originally Issued in Chinese)

TTY BIOPHARM COMPANY LIMITED

Statements of Comprehensive Income

For the years ended December 31, 2025 and 2024

(Expressed in Thousands of New Taiwan Dollar, Except for Earnings Per Share)

| | | 2025 | | 2024 | |
|------|--|---------------------|-----------|------------------|-----------|
| | | Amount | % | Amount | % |
| 4000 | Operating revenue (notes 6(p)and 7) | \$ 5,407,764 | 100 | 4,984,797 | 100 |
| 5000 | Operating costs (notes 6(c), (h), (l)and 12) | 2,350,437 | 43 | 2,142,747 | 43 |
| | Gross profit | 3,057,327 | 57 | 2,842,050 | 57 |
| 5910 | Less: Unrealized profit (loss) from sales | 33,360 | - | 29,550 | - |
| 5920 | Add: Realized profit (loss) from sales | 29,550 | 1 | 20,922 | - |
| | Gross profit, net | 3,053,517 | 58 | 2,833,422 | 57 |
| 6000 | Operating expenses (notes 6(h), (l)and 12): | | | | |
| 6100 | Selling expenses | 1,064,419 | 20 | 1,035,672 | 21 |
| 6200 | Administrative expenses (note 6(q)) | 338,470 | 6 | 335,955 | 6 |
| 6300 | Research and development expenses | 168,441 | 3 | 242,934 | 5 |
| 6450 | Expected credit losses (note 6(b)) | - | - | 600 | - |
| | | 1,571,330 | 29 | 1,615,161 | 32 |
| | Net operating income | 1,482,187 | 29 | 1,218,261 | 25 |
| | Non-operating income and losses (notes 6(r)and 7): | | | | |
| 7100 | Interest income | 13,221 | - | 10,121 | - |
| 7010 | Other income | 229,974 | 4 | 14,148 | - |
| 7020 | Other losses and gains, net(note 6(f)) | 2,194 | - | 46,142 | 1 |
| 7050 | Finance costs, net | (38,010) | (1) | (38,337) | (1) |
| 7070 | Share of profit of subsidiaries and associates accounted for using equity method, net (note 6(e)) | 292,906 | 5 | 526,163 | 11 |
| | | 500,285 | 8 | 558,237 | 11 |
| | Profit before tax | 1,982,472 | 37 | 1,776,498 | 36 |
| 7950 | Less: Income tax expenses (note 6(m)): | 423,347 | 8 | 326,876 | 7 |
| | Profit for the period | 1,559,125 | 29 | 1,449,622 | 29 |
| 8300 | Other comprehensive income: | | | | |
| 8310 | Components of other comprehensive income (loss) that will not be reclassified to profit or loss | | | | |
| 8311 | Gains on remeasurements of defined benefit plans (note 6(l)) | 96 | - | 9,292 | - |
| 8330 | Share of other comprehensive loss of subsidiaries and associates accounted for using equity method, components of other comprehensive income that will not be reclassified to profit or loss | 2,061 | - | 113,243 | 2 |
| 8349 | Income tax related to components of other comprehensive income that will not be reclassified to profit or loss | - | - | - | - |
| | Components of other comprehensive income that will not be reclassified to profit or loss | 2,157 | - | 122,535 | 2 |
| 8360 | Components of other comprehensive (loss) income that will be reclassified to profit or loss | | | | |
| 8361 | Exchange differences on translation | (37,267) | (1) | 133,464 | 3 |
| 8380 | Share of other comprehensive income of subsidiaries and associates accounted for using equity method, components of other comprehensive income that will be reclassified to profit or loss | 153 | - | 44 | - |
| 8399 | Income tax related to components of other comprehensive loss that may be reclassified to profit or loss | 7,362 | - | (26,700) | (1) |
| | Components of other comprehensive (loss) income that may be reclassified to profit or loss | (29,752) | (1) | 106,808 | 2 |
| 8300 | Other comprehensive (loss) income for the period, net of tax | (27,595) | (1) | 229,343 | 4 |
| | Total comprehensive income for the period | <u>\$ 1,531,530</u> | <u>28</u> | <u>1,678,965</u> | <u>33</u> |
| | Earnings per share, net of tax (note 6(o)) | | | | |
| | Basic earnings per share | \$ | 6.27 | \$ | 5.83 |
| | Diluted earnings per share | \$ | 6.26 | \$ | 5.82 |

(English Translation of Financial Statements Originally Issued in Chinese)

TTY BIOPHARM COMPANY LIMITED

Statements of Changes in Equity

For the years ended December 31, 2025 and 2024

(Expressed in Thousands of New Taiwan Dollar)

| | Share capital | | Retained earnings | | | Total other equity interest | | | | Total equity |
|---|---------------------|-----------------|-------------------|-----------------|----------------------------------|---|---|-----------------------------|------------------|--------------|
| | Ordinary shares | Capital surplus | Legal reserve | Special reserve | Unappropriated retained earnings | Exchange differences on translation of foreign financial statements | Unrealized gains (losses) on financial assets measured at fair value through other comprehensive income | Total other equity interest | | |
| Balance on January 1, 2024 | \$ 2,486,500 | 316,618 | 1,389,227 | 198,071 | 1,594,709 | (75,492) | 31,707 | (43,785) | 5,941,340 | |
| Net income | - | - | - | - | 1,449,622 | - | - | - | 1,449,622 | |
| Other comprehensive income | - | - | - | - | 9,292 | 106,808 | 113,243 | 220,051 | 229,343 | |
| Total comprehensive income | - | - | - | - | 1,458,914 | 106,808 | 113,243 | 220,051 | 1,678,965 | |
| Appropriation and distribution of retained earnings: | | | | | | | | | | |
| Legal reserve appropriated | - | - | 110,289 | - | (110,289) | - | - | - | - | |
| Cash dividends of ordinary share | - | - | - | - | (870,275) | - | - | - | (870,275) | |
| Other changes in capital surplus: | | | | | | | | | | |
| Changes in equity of investments accounted for using equity method | - | 284 | - | - | - | - | - | - | 284 | |
| Other changes in capital surplus | - | 134 | - | - | - | - | - | - | 134 | |
| Disposal of investments in equity instruments measured at fair value through other comprehensive income | - | - | - | - | 117,578 | - | (117,578) | (117,578) | - | |
| Balance on December 31, 2024 | 2,486,500 | 317,036 | 1,499,516 | 198,071 | 2,190,637 | 31,316 | 27,372 | 58,688 | 6,750,448 | |
| Net income | - | - | - | - | 1,559,125 | - | - | - | 1,559,125 | |
| Other comprehensive income | - | - | - | - | 96 | (29,752) | 2,061 | (27,691) | (27,595) | |
| Total comprehensive income | - | - | - | - | 1,559,221 | (29,752) | 2,061 | (27,691) | 1,531,530 | |
| Appropriation and distribution of retained earnings: | | | | | | | | | | |
| Legal reserve appropriated | - | - | 157,649 | - | (157,649) | - | - | - | - | |
| Cash dividends of ordinary share | - | - | - | - | (1,044,330) | - | - | - | (1,044,330) | |
| Other changes in capital surplus: | | | | | | | | | | |
| Changes in equity of investments accounted for using equity method | - | 121 | - | - | - | - | - | - | 121 | |
| Other changes in capital surplus | - | 246 | - | - | - | - | - | - | 246 | |
| Disposal of subsidiaries or investments accounted for using equity method | - | - | - | - | - | 282 | - | 282 | 282 | |
| Disposal of investments accounted for using the equity method / subsidiaries | - | 156 | - | - | (43) | - | - | - | 113 | |
| Disposal of investments in equity instruments measured at fair value through other comprehensive income | - | - | - | - | 24,097 | - | (24,097) | (24,097) | - | |
| Balance on December 31, 2025 | \$ 2,486,500 | 317,559 | 1,657,165 | 198,071 | 2,571,933 | 1,846 | 5,336 | 7,182 | 7,238,410 | |

(English Translation of Financial Statements Originally Issued in Chinese)

TTY BIOPHARM COMPANY LIMITED

Statements of Cash Flows

For the years ended December 31, 2025 and 2024

(Expressed in Thousands of New Taiwan Dollar)

| | <u>2025</u> | <u>2024</u> |
|---|--------------------|--------------------|
| Cash flows from (used in) operating activities: | | |
| Profit before tax | \$ 1,982,472 | 1,776,498 |
| Adjustments: | | |
| Adjustments to reconcile profit (loss): | | |
| Depreciation expense | 145,983 | 141,546 |
| Amortization expense | 34,472 | 42,164 |
| Expected credit losses | - | 600 |
| Interest expense | 38,010 | 38,337 |
| Interest income | (13,221) | (10,121) |
| Share of profit of investments accounted for using the equity method | (292,906) | (526,163) |
| Losses on disposal of property, plant and equipment | 1,800 | 79 |
| Reversal of impairment loss on non-financial assets | 18,184 | (2,000) |
| Unrealized profit from sales | 33,360 | 29,550 |
| Realized profit from sales | (29,550) | (20,922) |
| Gain from lease modification | - | (46) |
| Others | (6,341) | (6,341) |
| Total adjustments to reconcile (loss) profit | <u>(70,209)</u> | <u>(313,317)</u> |
| Changes in operating assets and liabilities: | | |
| Notes receivable | 2,549 | 7,145 |
| Accounts receivable | (111,750) | (13,397) |
| Other receivable | (12,755) | 6,563 |
| Inventories | (142,219) | (125,984) |
| Other current assets | (9,017) | 22,914 |
| Total changes in operating assets | <u>(273,192)</u> | <u>(102,759)</u> |
| Current contract liabilities | 17,157 | 20,508 |
| Notes payable | (32,023) | (21,821) |
| Accounts payable | (16,199) | 40,469 |
| Other payable | 116,437 | (54,181) |
| Other current liabilities | (2,947) | 170 |
| Net defined benefit liability | (435) | (571) |
| Decrease in other non-current liabilities | - | (33,400) |
| Total changes in operating liabilities | <u>81,990</u> | <u>(48,826)</u> |
| Total changes in operating assets and liabilities | <u>(191,202)</u> | <u>(151,585)</u> |
| Total adjustments | <u>(261,411)</u> | <u>(464,902)</u> |
| Cash inflow generated from operations | 1,721,061 | 1,311,596 |
| Interest received | 13,221 | 10,121 |
| Dividends received | 237,930 | 89,929 |
| Interest paid | (37,759) | (38,060) |
| Income taxes paid | (320,398) | (277,957) |
| Net cash flows from operating activities | <u>1,614,055</u> | <u>1,095,629</u> |
| Cash flows from (used in) investing activities: | | |
| Proceeds from disposal of investments accounted for using equity method | - | 290,250 |
| Acquisition of property, plant and equipment | (80,588) | (88,258) |
| Proceeds from disposal of property, plant and equipment | 1,134 | 3,632 |
| Increase in refundable deposits | (24,140) | - |
| Decrease in refundable deposits | - | 19,897 |
| Acquisition of intangible assets | (50,341) | (8,118) |
| Increase in other financial assets | (13,406) | - |
| Decrease in other financial assets | - | 239 |
| Increase in prepayments for business facilities | (9,465) | (35,142) |
| Increase in other non-current assets | (17,361) | (18,832) |
| Net cash flows (used in) from investing activities | <u>(194,167)</u> | <u>163,668</u> |
| Cash flows from (used in) financing activities: | | |
| Increase in short-term loans | 6,300,000 | 8,050,000 |
| Decrease in short-term loans | (6,800,000) | (8,300,000) |
| Proceeds from long-term borrowings | 400,000 | 500,000 |
| Repayments of long-term borrowings | (400,000) | (400,000) |
| Increase (decrease) in guarantee deposits | (10) | 41 |
| Payment of lease liabilities | (1,260) | (2,019) |
| Cash dividends paid | (1,044,330) | (870,275) |
| Dividends unclaimed by shareholders | 246 | 134 |
| Net cash flows used in financing activities | <u>(1,545,354)</u> | <u>(1,022,119)</u> |
| Effect of exchange rate changes on cash and cash equivalents | (23) | 6 |
| Increase (decrease) in cash and cash equivalents for the period | (125,489) | 237,184 |
| Cash and cash equivalents at beginning of period | 755,565 | 518,381 |
| Cash and cash equivalents at end of period | <u>\$ 630,076</u> | <u>755,565</u> |

Independent Auditors' Report

To the Board of Directors of TTY Biopharm Company Limited:

Opinion

We have audited the consolidated financial statements of TTY Biopharm Company Limited and its subsidiaries (“the Group”), which comprise the consolidated balance sheet as of December 31, 2025 and 2024, the consolidated statement of comprehensive income, changes in equity and cash flows for the years then ended, and notes to the consolidated financial statements, including a summary of material accounting policies.

In our opinion, based on our audits and the report of another auditor (please refer to the Other Matter paragraph), the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Group as of December 31, 2025 and 2024, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with the “Regulations Governing the Preparation of Financial Reports by Securities Issuers” and with the International Financial Reporting Standards (“IFRSs”), International Accounting Standards (“IASs”), Interpretations developed by the International Financial Reporting Interpretations Committee (“IFRIC”) or the former Standing Interpretations Committee (“SIC”) endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

Basis for Opinion

We conducted our audit in accordance with the Regulations Governing Financial Statements Audit and Attestation Engagements of Certified Public Accountants Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the Certified Public Accountants Code of Professional Ethics in Republic of China (“the Code”), and we have fulfilled our other ethical responsibilities in accordance with the Code. Based on our audits and the report of another auditor, we believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis of our opinion.

Other Matter

We did not audit the financial statements of PharmaEngine Inc, an associate of the Group, which represented investment in another entity accounted for using the equity method. Those statements were audited by another auditor, whose report has been furnished to us, and our opinion, insofar as it relates to the amounts included for certain equity-accounted investees, is based solely on the report of another auditor. The investment in the investee company constituted 9.26% and 10.46% of consolidated total assets as of December 31, 2025 and 2024, respectively, and the related share of profit of associates accounted for using the equity method constituted 3.28% and 16.71% of pre-tax net income for the years ended December 31, 2025 and 2024, respectively.

We have audited the financial statements of TTY Biopharm Company Limited as of and for the years ended December 31, 2025 and 2024, on which we have issued an unqualified opinion with another matter section, thereon.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. Key audit matters for the consolidated financial statements are stated as follows:

1. Occurrence of revenue from selling pharmaceuticals and chemical drugs

Please refer to Notes 4(p) of the consolidated financial statements for the accounting principles on revenue recognition. Revenues are recognized by net values of contract prices, less sales returns and allowances, after controls of the products are transferred to the customers.

Key audit matters:

The Group's sales is mainly from the selling of pharmaceuticals and chemical drugs. Because the customers are diversity and numerous, it takes longer time to verify sales transactions. Therefore, the occurrence in sales transactions is one of the important issue in performing our audit procedures.

Auditing procedures performed:

- Testing the effectiveness of the design and implementing the internal control system of sales and collection operation;
- Testing the samples of sales transaction before and after the balance sheet date to ensure the correctness of sales revenue;
- Inspecting the related documents to ensure the adequacy and reasonableness of revenue recognition.

2. Inventory valuation

Please refer to Notes 4(h) and 5 of the consolidated financial statements for the accounting principles on the inventory valuation, significant accounting assumptions and judgments, and major sources of estimation uncertainty.

Key audit matters:

The Group's primary operating items are manufacturing and processing various kinds of pharmaceuticals. The pharmaceutical industry in Taiwan is susceptible to the constant amendments of its law, resulting in large price fluctuation of pharmaceutical products, which will affect the carrying value of inventories to exceed its net value. Because of these uncertainties, the Group's revenue and income may be effected by the price fluctuations. If the assessment of the net realizable value of the inventory is not appropriate, it will lead to a material misstatement of the financial statements. Therefore, the assessment of the allowance for inventory valuation loss is considered one of the key audit matters in our audit.

Auditing procedures performed:

- Overviewing the stock ageing list, analyzing the movement of stock ageing by period;
- Obtaining the certificate documents to verify the correctness of the stock's expiry date; and
- Sampling the replacement cost and market price of inventories, and recalculating the net realizable value by marketing expense rate, to ensure the reasonableness of net realizable value adopted by the Group.

3. Goodwill Impairment Assessment

Please refer to Notes 4(n) non-financial asset impairment of the consolidated financial statements for the accounting policies on the impairment assessment of intangible assets; for significant accounting assumptions and judgments regarding goodwill, please refer to Note 5(b); for explanations on the goodwill impairment assessment, please refer to Note 6(j) Intangible Assets of the consolidated financial statements.

Key audit matters:

The goodwill of TTY Group arises from the premium paid (the acquisition price exceeding the book value) for acquiring 51% of ordinary shares outstanding of each of TOP Pharm Medicalware Co., Ltd. (TOP PM) and TOP Biological Technology Co., Ltd. (TOP BT) in 2024. The primary risk lies in the management's subjective judgment in assessing future cash flow assumptions, which are highly uncertain and may affect the evaluation of recoverable value. Therefore, the goodwill impairment test is one of the most critical assessment items for the accountant in auditing the financial statements of TTY Group.

Auditing procedures performed:

The primary audit procedures performed by us for the aforementioned key audit matter included verifying the Group management's assumptions against externally available information and performing professional assessments of the key parameters adopted by the management, such as the projected growth rates, discount rates, and gross margins. We also evaluated the accuracy of the management's past forecasts, including performing sensitivity analyses on the assumptions used in the impairment testing calculations.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and IFRSs, IASs, IFRC, SIC endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China, and for such internal control as management determines it is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance (including the Audit Committee) are responsible for overseeing the Group's financial reporting process.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with Standards on Auditing of the Republic of China, we exercise professional judgment and professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partners on the audit resulting in this independent auditors' report are Han, Yi-Lien and Chang, Stu-Ying.

KPMG

Taipei, Taiwan (Republic of China)

March 9, 2026

| | | December 31, 2025 | | December 31, 2024 | |
|----------------------------|--|-----------------------------|-------------------|--------------------------|-------------------|
| | | Amount | % | Amount | % |
| Assets | | | | | |
| Current assets: | | | | | |
| 1100 | Cash and cash equivalents (notes 6(a), (f) and (u)) | \$ 2,520,849 | 23 | 2,772,615 | 25 |
| 1120 | Current financial assets at fair value through other comprehensive income (notes 6(b) and (u)) | 30,743 | - | 77,015 | 1 |
| 1150 | Notes receivable, net (notes 6(c), (f) and (u)) | 22,448 | - | 22,847 | - |
| 1170 | Accounts receivable, net (notes 6(c), (f) and (u)) | 1,458,787 | 13 | 1,323,440 | 12 |
| 1180 | Accounts receivable due from related parties, net (notes 6(c), (u) and 7) | 36,644 | - | 7,385 | - |
| 1200 | Other receivables, net (notes 6(u) and 7) | 36,456 | - | 23,181 | - |
| 130X | Inventories (notes 6(d), (f) and 9) | 1,389,009 | 12 | 1,270,007 | 12 |
| 1410 | Prepayments | 63,201 | 1 | 57,911 | 1 |
| 1476 | Other current financial assets (notes 6(f), (k) and (u)) | 437,000 | 4 | 232,000 | 2 |
| 1470 | Other current assets (note 6(k)) | 13,677 | - | 6,667 | - |
| | | <u>6,008,814</u> | <u>53</u> | <u>5,793,068</u> | <u>53</u> |
| Non-current assets: | | | | | |
| 1517 | Non-current financial assets at fair value through other comprehensive income (notes 6(b) and (u)) | 191,137 | 2 | 198,205 | 2 |
| 1550 | Investments accounted for using the equity method, net (note 6(e)) | 1,715,742 | 15 | 1,719,819 | 16 |
| 1600 | Property, plant and equipment (notes 6(f), (h) and 9) | 2,183,344 | 19 | 2,235,004 | 21 |
| 1755 | Right-of-use assets (note 6(f)) | 15,568 | - | 11,116 | - |
| 1760 | Investment property, net (note 6(i)) | 130,864 | 1 | 132,194 | 1 |
| 1780 | Intangible assets (notes 6(f), (j) and 9) | 425,172 | 4 | 371,341 | 3 |
| 1840 | Deferred tax assets | 65,803 | 1 | 58,523 | 1 |
| 1915 | Prepayments for business facilities | 17,263 | - | 40,233 | - |
| 1920 | Refundable deposits paid (note 6(u)) | 55,416 | - | 30,463 | - |
| 1984 | Other non-current financial assets (notes 6(k), (u) and 8) | 457,072 | 4 | 176,817 | 2 |
| 1990 | Other non-current assets (notes 6(f) and (k)) | 81,874 | 1 | 95,983 | 1 |
| | | <u>5,339,255</u> | <u>47</u> | <u>5,069,698</u> | <u>47</u> |
| Total assets | | <u>\$ 11,348,069</u> | <u>100</u> | <u>10,862,766</u> | <u>100</u> |

| | | December 31, 2025 | | December 31, 2024 | |
|---|---|-----------------------------|-------------------|--------------------------|-------------------|
| | | Amount | % | Amount | % |
| Liabilities and Equity | | | | | |
| Current liabilities: | | | | | |
| 2100 | Short-term borrowings (notes 6(l) and (u)) | \$ 700,000 | 6 | 1,200,000 | 11 |
| 2130 | Contract liabilities-current (note 6(r)) | 53,699 | - | 34,340 | - |
| 2150 | Notes payable (notes 6(f) and (u)) | 9,640 | - | 50,399 | - |
| 2170 | Accounts payable (notes 6(f) and (u)) | 261,137 | 2 | 275,759 | 3 |
| 2219 | Other payables (notes 6(s) and (u)) | 742,539 | 7 | 649,139 | 6 |
| 2230 | Current tax liabilities (note 6(f)) | 323,677 | 3 | 228,802 | 2 |
| 2280 | Current lease liabilities (notes 6(f) and (u)) | 8,352 | - | 930 | - |
| 2300 | Other current liabilities (note 6(f)) | 40,789 | - | 23,040 | - |
| 2320 | Long-term liabilities, current portion (notes 6(m) and (u)) | 500,000 | 5 | 400,000 | 4 |
| | | <u>2,639,833</u> | <u>23</u> | <u>2,862,409</u> | <u>26</u> |
| Non-current liabilities: | | | | | |
| 2540 | Long-term borrowings (notes 6(m) and (u)) | - | - | 100,000 | 1 |
| 2570 | Deferred tax liabilities | 363,187 | 3 | 359,239 | 3 |
| 2580 | Non-current lease liabilities (notes 6(f) and (u)) | 7,396 | - | 10,199 | - |
| 2640 | Net defined benefit liability, non-current | 17,008 | - | 17,539 | - |
| 2645 | Guarantee deposits received (note 6(u)) | 2,454 | - | 2,440 | - |
| 2670 | Other non-current liabilities (note 6(u)) | 266,849 | 2 | - | - |
| | | <u>656,894</u> | <u>5</u> | <u>489,417</u> | <u>4</u> |
| | Total liabilities | <u>3,296,727</u> | <u>28</u> | <u>3,351,826</u> | <u>30</u> |
| Equity attributable to owners of parent (note 6(p)): | | | | | |
| 3100 | Share capital | 2,486,500 | 22 | 2,486,500 | 23 |
| 3200 | Capital surplus (note 6(e)) | 317,559 | 3 | 317,036 | 3 |
| 3310 | Legal reserve | 1,657,165 | 15 | 1,499,516 | 14 |
| 3320 | Special reserve | 198,071 | 2 | 198,071 | 2 |
| 3350 | Unappropriated retained earnings | 2,571,933 | 23 | 2,190,637 | 20 |
| 3400 | Other equity interest | 7,182 | - | 58,688 | 1 |
| | Equity attributable to owners of parent: | <u>7,238,410</u> | <u>65</u> | <u>6,750,448</u> | <u>63</u> |
| 36XX | Non-controlling interests (notes 6(g) and (p)) | 812,932 | 7 | 760,492 | 7 |
| | Total equity | <u>8,051,342</u> | <u>72</u> | <u>7,510,940</u> | <u>70</u> |
| | Total liabilities and equity | <u>\$ 11,348,069</u> | <u>100</u> | <u>10,862,766</u> | <u>100</u> |

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES

Consolidated Statements of Comprehensive Income

For the years ended December 31, 2025 and 2024

(Expressed in Thousands of New Taiwan Dollar, Except for Earnings Per Share)

| | | 2025 | | 2024 | |
|------|--|---------------------|-----------|------------------|-----------|
| | | Amount | % | Amount | % |
| 4000 | Operating revenue (notes 6(r) and 7) | \$ 6,452,948 | 100 | 5,893,847 | 100 |
| 5000 | Operating costs (notes 6(d), (n) and 12) | 2,732,425 | 42 | 2,479,113 | 42 |
| | Gross profit | 3,720,523 | 58 | 3,414,734 | 58 |
| 5910 | Less: Unrealized profit (loss) from sales | 12,023 | - | 12,053 | - |
| 5920 | Add: Realized profit (loss) from sales | 12,053 | - | 13,490 | - |
| | Gross profit, net | 3,720,553 | 58 | 3,416,171 | 58 |
| 6000 | Operating expenses (notes 6(n), (s) and 12): | | | | |
| 6100 | Selling expenses | 1,365,052 | 21 | 1,284,233 | 22 |
| 6200 | Administrative expenses | 456,298 | 7 | 465,327 | 8 |
| 6300 | Research and development expenses | 194,348 | 3 | 271,392 | 4 |
| 6450 | Expected credit losses (note 6(c)) | 896 | - | 1,363 | - |
| | Total operating expenses | 2,016,594 | 31 | 2,022,315 | 34 |
| | Net operating income | 1,703,959 | 27 | 1,393,856 | 24 |
| | Non-operating income and expenses (note 6(t)): | | | | |
| 7100 | Interest income | 75,076 | 1 | 85,760 | 1 |
| 7010 | Other income | 227,881 | 4 | 12,833 | - |
| 7020 | Other gains and losses, net (note 7) | (7,948) | - | 31,930 | 1 |
| 7050 | Finance costs, net | (38,656) | (1) | (38,739) | (1) |
| 7060 | Share of profit of associates accounted for using the equity method, net (note 6(e)) | 164,866 | 3 | 400,047 | 7 |
| 7055 | Total non-operating income and expenses | 421,219 | 7 | 491,831 | 8 |
| | Profit before tax | 2,125,178 | 34 | 1,885,687 | 32 |
| 7950 | Less: Income tax expenses (note 6(o)) | 470,474 | 7 | 366,333 | 6 |
| | Profit for the period | 1,654,704 | 27 | 1,519,354 | 26 |
| 8300 | Other comprehensive income : | | | | |
| 8310 | Components of other comprehensive income (loss) that will not be reclassified to profit or loss | | | | |
| 8311 | Gains on remeasurements of defined benefit plans (note 6(n)) | 96 | - | 9,292 | - |
| 8316 | Unrealized (losses) gains from investments in equity instruments measured at fair value through other comprehensive income | (7,293) | - | 220,157 | 4 |
| 8320 | Share of other comprehensive income (losses) of associates accounted for using equity method, components of other comprehensive income that will not be reclassified to profit or loss | 6,180 | - | (11,102) | - |
| 8349 | Income tax related to components of other comprehensive income that will not be reclassified to profit or loss | - | - | - | - |
| | Components of other comprehensive (losses) income that will not be reclassified to profit or loss | (1,017) | - | 218,347 | 4 |
| 8360 | Components of other comprehensive income (losses) that will be reclassified to profit or loss | | | | |
| 8361 | Exchange differences on translation | (37,083) | (1) | 133,568 | 2 |
| 8399 | Income tax related to components of other comprehensive income (loss) that will be reclassified to profit or loss | 7,362 | - | (26,700) | - |
| | Components of other comprehensive (loss) income that will be reclassified to profit or loss | (29,721) | (1) | 106,868 | 2 |
| 8300 | Other comprehensive (loss) income | (30,738) | (1) | 325,215 | 6 |
| | Total comprehensive income for the period | \$ 1,623,966 | 26 | 1,844,569 | 32 |
| | Profit attributable to: | | | | |
| 8610 | Owners of parent | \$ 1,559,125 | 26 | 1,449,622 | 25 |
| 8620 | Non-controlling interests | 95,579 | 1 | 69,732 | 1 |
| | | \$ 1,654,704 | 27 | 1,519,354 | 26 |
| | Comprehensive income attributable to: | | | | |
| | Owners of parent | \$ 1,531,530 | 24 | 1,678,965 | 29 |
| | Non-controlling interests | 92,436 | 2 | 165,604 | 3 |
| | | \$ 1,623,966 | 26 | 1,844,569 | 32 |
| | Earnings per share, net of tax (note 6(q)) | | | | |
| 9750 | Basic earnings per share | \$ 6.27 | | 5.83 | |
| 9850 | Diluted earnings per share | \$ 6.26 | | 5.82 | |

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES

Consolidated Statements of Changes in Equity

For the years ended December 31, 2025 and 2024

(Expressed in Thousands of New Taiwan Dollar)

| | Equity attributable to owners of parent | | | | | | | | | | |
|---|---|-----------------|-------------------|-----------------|----------------------------------|-------------------------------------|---|-----------------------------|---|---------------------------|------------------|
| | Share capital | | Retained earnings | | | | Total other equity interest | | | | |
| | Ordinary shares | Capital surplus | Legal reserve | Special reserve | Unappropriated retained earnings | Exchange differences on translation | Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income | Total other equity interest | Total equity attributable to owners of parent | Non-controlling interests | Total equity |
| Balance at January 1, 2024 | \$ 2,486,500 | 316,618 | 1,389,227 | 198,071 | 1,594,709 | (75,492) | 31,707 | (43,785) | 5,941,340 | 564,802 | 6,506,142 |
| Net income | - | - | - | - | 1,449,622 | - | - | - | 1,449,622 | 69,732 | 1,519,354 |
| Other comprehensive income | - | - | - | - | 9,292 | 106,808 | 113,243 | 220,051 | 229,343 | 95,872 | 325,215 |
| Total comprehensive income | - | - | - | - | 1,458,914 | 106,808 | 113,243 | 220,051 | 1,678,965 | 165,604 | 1,844,569 |
| Appropriation and distribution of retained earnings: | | | | | | | | | | | |
| Legal reserve appropriated | - | - | 110,289 | - | (110,289) | - | - | - | - | - | - |
| Cash dividends of ordinary share | - | - | - | - | (870,275) | - | - | - | (870,275) | - | (870,275) |
| Other changes in capital surplus: | | | | | | | | | | | |
| Changes in equity of investments accounted for using the equity method | - | 253 | - | - | - | - | - | - | 253 | - | 253 |
| Other changes in capital surplus | - | 134 | - | - | - | - | - | - | 134 | - | 134 |
| Changes in ownership interests in subsidiaries | - | 31 | - | - | - | - | - | - | 31 | 23 | 54 |
| Changes in non-controlling interests | - | - | - | - | - | - | - | - | - | 51,453 | 51,453 |
| Disposal of investments in equity instruments measured at fair value through other comprehensive income | - | - | - | - | 117,578 | - | (117,578) | (117,578) | - | - | - |
| Distribution of dividend by subsidiaries to non-controlling interests | - | - | - | - | - | - | - | - | - | (21,390) | (21,390) |
| Balance at December 31, 2024 | 2,486,500 | 317,036 | 1,499,516 | 198,071 | 2,190,637 | 31,316 | 27,372 | 58,688 | 6,750,448 | 760,492 | 7,510,940 |
| Profit (loss) | - | - | - | - | 1,559,125 | - | - | - | 1,559,125 | 95,579 | 1,654,704 |
| Other comprehensive income | - | - | - | - | 96 | (29,752) | 2,061 | (27,691) | (27,595) | (3,143) | (30,738) |
| Total comprehensive income | - | - | - | - | 1,559,221 | (29,752) | 2,061 | (27,691) | 1,531,530 | 92,436 | 1,623,966 |
| Appropriation and distribution of retained earnings: | | | | | | | | | | | |
| Legal reserve appropriated | - | - | 157,649 | - | (157,649) | - | - | - | - | - | - |
| Cash dividends of ordinary share | - | - | - | - | (1,044,330) | - | - | - | (1,044,330) | - | (1,044,330) |
| Other changes in capital surplus: | | | | | | | | | | | |
| Changes in equity of associates and joint ventures accounted for using equity method | - | 121 | - | - | - | - | - | - | 121 | - | 121 |
| Other changes in capital surplus | - | 246 | - | - | - | - | - | - | 246 | - | 246 |
| Disposal of subsidiaries or investments accounted for using equity method | - | - | - | - | - | 282 | - | 282 | 282 | 180 | 462 |
| Changes in ownership interests in subsidiaries | - | 156 | - | - | (43) | - | - | - | 113 | 111 | 224 |
| Disposal of investments in equity instruments measured at fair value through other comprehensive income | - | - | - | - | 24,097 | - | (24,097) | (24,097) | - | - | - |
| Distribution of dividend by subsidiaries to non-controlling interests | - | - | - | - | - | - | - | - | - | (40,287) | (40,287) |
| Balance at December 31, 2025 | \$ 2,486,500 | 317,559 | 1,657,165 | 198,071 | 2,571,933 | 1,846 | 5,336 | 7,182 | 7,238,410 | 812,932 | 8,051,342 |

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)
TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Consolidated Statements of Cash Flows
For the years ended December 31, 2025 and 2024
(Expressed in Thousands of New Taiwan Dollar)

| | 2025 | 2024 |
|---|---------------------|--------------------|
| Cash flows from (used in) operating activities: | | |
| Profit before tax | \$ 2,125,178 | 1,885,687 |
| Adjustments: | | |
| Adjustments to reconcile profit (loss): | | |
| Depreciation expenses | 158,266 | 155,842 |
| Amortization expenses | 38,311 | 46,507 |
| Expected (reversal of) credit impairment losses | 896 | 1,363 |
| Interest expenses | 38,656 | 38,739 |
| Interest income | (75,076) | (85,760) |
| Dividend income | (6,557) | (6,528) |
| Shares of profit of investments accounted for using the equity method | (164,866) | (400,047) |
| Gain on disposal of property, plant and equipment | 1,800 | 946 |
| Gain on disposal of investments accounted for using equity method | (946) | - |
| Impairment loss on non-financial assets | 18,184 | 6,799 |
| Unrealized profit from sales | 12,023 | 12,053 |
| Realized profit from sales | (12,053) | (13,490) |
| Gain from lease modification | - | (127) |
| Total adjustments to reconcile profit (loss) | <u>8,638</u> | <u>(243,703)</u> |
| Changes in operating assets and liabilities: | | |
| Changes in operating assets: | | |
| Notes receivable | 399 | 15,201 |
| Accounts receivable | (167,144) | 35,071 |
| Other receivables | (10,200) | 3,861 |
| Inventories | (119,080) | (161,267) |
| Prepayments and other current assets | (12,171) | 24,263 |
| Total changes in operating assets | <u>(308,196)</u> | <u>(82,871)</u> |
| Changes in operating liabilities: | | |
| Contract liabilities | 19,368 | 20,106 |
| Notes payable | (40,759) | (40,649) |
| Accounts payable | (13,343) | (10,209) |
| Other payable | 93,185 | (5,633) |
| Other current liabilities | 18,056 | 6,162 |
| Net defined benefit liability | (435) | (571) |
| Total changes in operating liabilities | <u>76,072</u> | <u>(30,794)</u> |
| Total changes in operating assets and liabilities | <u>(232,124)</u> | <u>(113,665)</u> |
| Total adjustments | <u>(223,486)</u> | <u>(357,368)</u> |
| Cash inflow generated from operations | 1,901,692 | 1,528,319 |
| Interest received | 71,800 | 87,878 |
| Dividends received | 198,509 | 68,697 |
| Interest paid | (38,405) | (38,462) |
| Income taxes paid | (371,759) | (297,056) |
| Net cash flows from operating activities | <u>1,761,837</u> | <u>1,349,376</u> |
| Cash flows from (used in) investing activities: | | |
| Acquisition of financial assets at fair value through other comprehensive income | - | (2,489) |
| Proceeds from disposal of financial assets at fair value through other comprehensive income | 46,047 | 221,121 |
| Proceeds from disposal of investments accounted for using equity method | 1,470 | - |
| Net cash outflow from acquisition of subsidiaries | - | (242,870) |
| Acquisition of property, plant and equipment | (81,981) | (89,138) |
| Proceeds from disposal of property, plant and equipment | 1,134 | 3,927 |
| (Increase) decrease in refundable deposits paid | (24,961) | 20,285 |
| Acquisition of intangible assets | (56,224) | (9,135) |
| Increase in other financial assets | (218,406) | (90,452) |
| Increase in prepayments for business facilities | (12,627) | (36,021) |
| Increase in other non-current assets | (21,815) | (18,791) |
| Net cash flows used in investing activities | <u>(367,363)</u> | <u>(243,563)</u> |
| Cash flows from (used in) financing activities: | | |
| Increase in short-term loans | 6,300,000 | 8,050,000 |
| Decrease in short-term loans | (6,800,000) | (8,300,000) |
| Proceeds from long-term borrowings | 400,000 | 500,000 |
| Repayments of long-term borrowings | (400,000) | (400,000) |
| Increase in guarantee deposits received | 14 | 8 |
| Payment of lease liabilities | (8,609) | (9,767) |
| Cash dividends paid | (1,044,330) | (870,275) |
| Dividends unclaimed by shareholders | - | 188 |
| Cash dividends paid to non-controlling interests | (40,287) | (21,390) |
| Net cash flows used in financing activities | <u>(1,593,212)</u> | <u>(1,051,236)</u> |
| Effect of exchange rate changes on cash and cash equivalents | <u>(53,028)</u> | <u>97,018</u> |
| Net (Decrease) increase in cash and cash equivalents | <u>(251,766)</u> | <u>151,595</u> |
| Cash and cash equivalents at beginning of period | <u>2,772,615</u> | <u>2,621,020</u> |
| Cash and cash equivalents at end of period | <u>\$ 2,520,849</u> | <u>2,772,615</u> |

Attachment 6

TTY Biopharm Company Limited

Earnings Distribution Table

2025

Unit: NT\$

| Item | Amount | Notes |
|---|---------------|--|
| Unappropriated Retained Earnings at Beginning of Period | 988,657,527 | |
| Add: 2025 Retained Earnings Adjustments | 24,150,665 | Remeasurement of defined benefit pension plan liability, and recognition of gains and losses from subsidiaries' disposal of equity instrument investments measured at fair value through other comprehensive income transferred directly to retained earnings. |
| Add: Net Income After Tax for 2025 | 1,559,125,105 | |
| Less: Appropriation of 10% Legal Reserve | (158,327,577) | |
| Less: Appropriation of Special Reserve | 0 | |
| Distributable Earnings for the Current Period: | 2,413,605,720 | |
| Distribution Items: | | |
| Cash Dividends | 1,118,924,816 | Cash Dividend of NT\$4.50 per share |
| Unappropriated Retained Earnings at End of Period | 1,294,680,904 | |

Note 1: The share capital is calculated based on 248,649,959 shares.

Note 2: The current earnings distribution shall prioritize the earnings from fiscal year 2025.

Chairman: Chuan Lin

President: Ching-Lan Hou

Chief Accountant: Wei-Chuan Wang

Attachment 7

TTY Biopharm Company Limited

Comparison Table of Provisions Before and After Amendment to the “Procedures for Acquisition or Disposal of Assets”

| Original Text | Amended Text | Reason for Amendment |
|--|--|---|
| <p>Article 7</p> <p>Total amounts of real property and right-of-use assets thereof or securities acquired by the company and each subsidiary for business use, and limits on individual securities:</p> <p>I. The aggregate amount of real property and right-of-use assets thereof, or securities, purchased by the Company for non-operating purposes shall not exceed the higher of 150% of the Company’s paid-in capital or <u>100%</u> of equity attributable to owners of the parent as reported in the most recent financial statements; investment in any individual security shall not exceed the <u>Company’s paid-in capital</u>; and the aggregate amount of short-term investments and undisposed idle assets or real property held shall not exceed 70% of equity attributable to owners of the parent as reported in the Company’s most recent financial statements.</p> <p>II. The aggregate amount of real property and right-of-use assets thereof, or securities, purchased by each subsidiary for non-operating purposes shall not exceed the higher of 150% of such subsidiary’s paid-in capital or 100% of equity attributable to owners of the parent as reported in the most recent financial statements; investment in any individual security shall not exceed <u>100% of such subsidiary’s paid-in capital</u>; and</p> | <p>Article 7</p> <p>Total amounts of real property and right-of-use assets thereof or securities acquired by the company and each subsidiary for business use, and limits on individual securities:</p> <p>I. The aggregate amount of real property and right-of-use assets thereof, or securities, purchased by the Company for non-operating purposes shall not exceed the higher of <u>150%</u> of the Company’s paid-in capital or 150% of equity attributable to owners of the parent as reported in the most recent financial statements; investment in any individual security shall not exceed <u>100% of equity attributable to owners of the parent as reported in the most recent financial statements</u>; and the aggregate amount of short-term investments and undisposed idle assets or real property held shall not exceed 70% of equity attributable to owners of the parent as reported in the Company’s most recent financial statements.</p> <p>II. The aggregate amount of real property and right-of-use assets thereof, or securities, purchased by each subsidiary for non-operating purposes shall not exceed the higher of 150% of such subsidiary’s paid-in capital or 100% of equity attributable to owners of the parent as reported in the most recent financial statements; investment in any individual security <u>shall not</u></p> | <p>Amended in accordance with the Company’s operational requirements.</p> |

| Original Text | Amended Text | Reason for Amendment |
|---|--|------------------------------|
| <p>the aggregate amount of short-term investments and undisposed idle assets or real property held shall not exceed 70% of equity attributable to owners of the parent as reported in such subsidiary's most recent financial statements.</p> | <p><u>exceed 150% of equity attributable to owners of the parent as reported in the most recent financial statements</u>; and the aggregate amount of short-term investments and undisposed idle assets or real property held shall not exceed 70% of equity attributable to owners of the parent as reported in such subsidiary's most recent financial statements.</p> | |
| <p>Article 15 Supplementary Provisions: Matters not addressed in these Procedures shall be handled in accordance with applicable laws and regulations and the Company's relevant internal rules. These Procedures were established on May 22, 1988. The 1st Amendment was made on March 24, 2000 The 2nd Amendment was made on May 13, 2002 The 3rd Amendment was made on May 19, 2003 The 4th Amendment was made on June 21, 2007 The 5th Amendment was made on June 22, 2012 The 6th Amendment was made on June 24, 2014 The 7th Amendment was made on June 16, 2017 The 8th Amendment was made on June 25, 2019 The 9th Amendment was made on May 26, 2022 The 10th Amendment was made on May 30, 2024</p> | <p>Article 15 Supplementary Provisions: Matters not addressed in these Procedures shall be handled in accordance with applicable laws and regulations and the Company's relevant internal rules. These Procedures were established on May 22, 1998. The 1st Amendment was made on March 24, 2000 The 2nd Amendment was made on May 13, 2002 The 3rd Amendment was made on May 19, 2003 The 4th Amendment was made on June 21, 2007 The 5th Amendment was made on June 22, 2012 The 6th Amendment was made on June 24, 2014 The 7th Amendment was made on June 16, 2017 The 8th Amendment was made on June 25, 2019 The 9th Amendment was made on May 26, 2022 The 10th Amendment was made on May 30, 2024 <u>The 11th Amendment was made on May 28, 2026</u></p> | <p>Amendment date added.</p> |